Some investors lately prefer to invest in the commodity sector like gold or silver and base metals like copper and zinc. Some have made a lot of money! I've tried to do some of that too! But the health care sector (in this case, microcap Biotech) is also an important source of possible investment gain. But there are never any guarantees. Do your own due dilligence!
I am hopeful that I will make some money as tax time is rapidly approaching and the Un-Justin Trudeau and the unpredictable Danielle Smith (Alberta) both need to be paid their due compensation. And each new year brings more such bills that need to be paid!
For your perusal and education this is the company that I have most recently bought into. If you like, listen to the videos or do an internet search for more information. I am personally no expert! But when it comes to this particular science, the company's managers seem to be the most knowledgeable people to best inform. Give them a listen!
This company has most recently picked up some pharmaceutical intellectual property rights (patents) worth about 200 million dollars for only 750,000 in cash and 250,000 shares of BIOV stock. The bankrupt company (IMV) whose intellectual property that they acquired had burned through most of their cash doing expensive phase three clinical trials without a more well funded partner (which is a very time consuming process using hundreds of very sick patients). Phase one trials are less expensive to run by a start up company (look it up on the internet!). The cash burn rate is much cheaper during the preliminary phase one trials.
So BioVaxys is first focusing on license proposals (royalty revenue streams) with other partners and will be limiting their initial laboratory trials to allergy desensitation products when they find the proper laboratory facility to do their best work. Perhaps it will be in Nova Scotia? That remains to be determined. But they already have many of their necessary staff! And many former employees of IMV still remain available to contact for hiring. Many are now working in a diverse set of University labs.
This company remains a work in progress but that is what a start up company, first appears to be. It is still trying to best define its most immediate goals. I hope that this is a fair assessment of their present situation and strategy.
As I basically understand the concept, the goal is to reduce any initial stock dilution by promoting revenue streams through the licencing of patents to potential partners and/or by letting bigger phamaceutical partners bring any needed, later phase, more expensive trials to fruition and produce many of their biotech products for sale to the pharmaceutical market. They also intend to partner with University teams as necessary to help formulate new or similar products by continuing to develop what intellectual property that BioVaxys has already acquired.
These are early days. And many possibilities do exist for a company with many inexpensively acquired patents that originally cost many millions of dollars to develop and better define.
It is a complicated story! But that is the nature of a start up company with a lot of patents to develop and promote to a market place for the benefit of the health care system and for the greater good of its all of its shareholder base.
They have a novel and unique patented lipid based process that delivers appropriate biochemical drugs directly to the source of a patient's illness. Their lipid structure is a longer lasting one! It's unique structure allows the fat to contain and carry many different amounts of drug. That is different than the smaller amounts that much of the competition's lipid formulations are able to contain.
And fewer drug exposures would be necessary for a proper efficacy of treatment. Because this novel lipid method (DPX) of drug transport has a longer life, toxic side effects are less pronounced to the rest of the body! This is quite an accomplishment!
They have a good business model that was recently remodelled with some good luck in an astute and timely, valuable acquisition of biochemical knowledge. A lot of doors still need to be opened for the best of success! The CEO is strongly motivated since he owns a lot of shares! He is a very excited about the company's future prospects. But where is the best place to start? Listen to the company's video presentations!
And there always remains the potential for a suitably large sized M&A at any time when a small company's growth strategy becomes more successful than any of the rest of the equally sized competition.
I picked up about three hundred thousand 7.5 cent shares in my TFSA and RIFF accounts. These shares still seem pretty cheap to me! But for how long? When it comes to price, how high can it go?
This is a very small biotech company. But it has a wealth of different biotech opportunities to share with the now more demanding phamaceutical industry!
The DPX platform offers to provide a more efficacious method of transporting and maintaining insitu phamaceutical drugs to better battle against the bane of cancer and other painful infirmities such as inflamation or allergies when it is necessary to deal with our own uncooperative immune system when it fails to work at its best to serve our needs!
If BioVaxys shareholders make a little money in the process of healing the sick, there is nothing wrong with that!
I am confident that this will be a good investment.
And the price is right for me!
All the best, Java
https://www.biovaxys.com/ https://youtu.be/jS09q8WwBPw?si=JezjUkYJhXIBihUm https://youtu.be/jS09q8WwBPw?si=X8g_y4oLn8PEheTE https://youtu.be/92rcdnjSKfM?si=vxCXifWQLle5PTJo https://stockhouse.com/opinion/independent-reports/2024/10/08/how-biovaxys-dpx-platform-creates-anti-cancer-immune-response https://stockhouse.com/opinion/interviews/2024/07/30/revolutionizing-immunotherapies-with-groundbreaking-dpx-platform https://www.paidpromotionalmessages.com/companies/news/978266/biovaxys-technology-to-expand-cancer-vaccine-platform-with-investigator-sponsored-trial-of-colorectal-cancer-therapy-978266.html https://www.paidpromotionalmessages.com/companies/news/981069/biovaxys-files-to-expand-international-cervical-cancer-vaccine-patent-protection-981069.html